#USA #New York #Class Action #Intellia Therapeutics #NTLA

Attention Intellia Investors

The Gross Law Firm has recently notified shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) regarding a pending class action lawsuit. This notice is crucial for any investors who acquired shares during the specified class period, which runs from July 30, 2024, to January 8, 2025. Shareholders are encouraged to contact the firm to discuss the potential for lead plaintiff appointments. It's important to note that being appointed as a lead plaintiff is not a prerequisite for recovering any losses.

Background of the Lawsuit

The allegations within the complaint highlight that Intellia's executives provided misleading information about its Phase 1/2 clinical study assessing NTLA-3001, aimed at treating alpha-1 antitrypsin deficiency-related lung disease. The lawsuit suggests that the defendants expressed undue confidence about the company's research timelines, asserting that the first patient would be dosed in the latter half of 2024. However, they failed to disclose critical information that the demand for viral-based therapies was plummeting due to the scientific community's growing preference for non-viral delivery methods, known for their cost-effectiveness and developmental efficiency. This oversight rendered NTLA-3001 an unviable focus for Intellia's efforts.

On January 9, 2025, the situation escalated when Intellia announced a significant reorganization. The company stated that it would halt all NTLA-3001-related research and implement a 27% reduction in its workforce, leading to a drastic shift in resource allocation towards other pharmaceutical developments. Consequently, this led to the cancellation of the once-promising NTLA-3001 program. The subsequent drop in Intellia's stock price was significant, plummeting from $12.02 per share on January 8 to $10.20 by January 10, illustrating the impact of these revelations.

Important Dates

The deadline for shareholders to seek an appointment as lead plaintiff is approaching rapidly, set for April 14, 2025. Interested parties should not hesitate to register information regarding their shares in this class action. Registration can be done through the specified link, and the firm will ensure shareholders receive continuous updates about the lawsuit's progress through a specialized portfolio monitoring service—at no cost or obligation.

Why Engage with The Gross Law Firm?

As a nationally acclaimed class action law firm, The Gross Law Firm is dedicated to protecting the rights of investors who have fallen victim to corporate deceit, fraud, and illegal practices. Their mission includes holding companies accountable for their actions and ensuring a commitment to responsible corporate citizenship. Specifically, their focus is on helping investors claim compensation for losses incurred due to misleading statements or the omission of vital information that artificially inflated stock prices.

If you're an Intellia shareholder affected by the company's recent announcements, consider reaching out to discuss your rights and options regarding this class action lawsuit. The Gross Law Firm stands ready to assist in navigating this complex situation and to advocate on behalf of affected investors.

For further inquiries or to express your interest in joining this class action, please contact:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903